Conquering Diseases

Resolve-It: A Study Of A New Investigational Drug For Patients With Nonalcoholic Steatohepatitis (Nash) And Fibrosis.

Description

Nonalcoholic Steatohepatitis (NASH) is a disease that results when fat accumulates in the liver and eventually causes inflammation and scarring called fibrosis. The purpose of this study is to test whether an experimental drug, Elafibranor, is safe and effective in treating advanced scarring of the liver due to NASH.

Overview

Eligible patients will be randomly assigned to take study drug or placebo. Neither you nor the researchers will know which you are taking. Study visits occur approximately once every 3 months for the first 18th months, then every 24 weeks after that. At these visits researchers will ask you questions about your health, medications you are taking, and if you are having any problems with your health.

What we're hoping for

To find out if the study drug, Elafibranor, is safe and effective for treating patients with NASH and fibrosis

Additional Information

ClinicalTrials.gov Identifier: NCT02704403

 Principal Investigator

Gyongyi  Szabo, MD

University of Massachusetts Medical School

 Study Contact

Monique  Rinner

774 442 1982

monique.rinner@umassmemorial.org

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989